In addition to advancing the medical and scientific knowledge of MAPS PBC’s study drugs and/or products, the purpose of the investigator-initiated trial and studies program is to provide support for external clinical research in areas that help discover new opportunities to address unmet medical needs.

Consideration will be given to applications proposing to investigate the following:

• 3,4-Methylenedioxymethamphetamine (MDMA)

Note: MDMA-AT has not been approved by any regulatory agency. The safety and efficacy of MDMA-AT have not been established for the treatment of PTSD.